Kyowa Kirin
Kyowa Kirin is a Japan-based global specialty pharmaceutical company focusing on nephrology, oncology, immunology & allergy, and neurology, utilizing advanced antibody technologies for drug discovery and commercialization.
Company Overview
Kyowa Kirin is a Japan-based global specialty pharmaceutical company. The company focuses on core therapeutic areas including nephrology, oncology, immunology & allergy, and neurology. With a global network of subsidiaries in Japan, North America, Asia Pacific, and EMEA regions, Kyowa Kirin utilizes state-of-the-art antibody technologies for drug discovery and commercialization.
Products
Kyowa Kirin offers a range of pharmaceutical products that address various medical needs. The main products include Crysvita®, POTELIGEO®, REGPARA®, Nouriast®/Nourianz®, ESPO®/NESP®, and GRAN®/Peglasta®/Neulasta®. These products cater to different therapeutic areas and are part of the company's commitment to improving patient outcomes worldwide.
History
Kyowa Kirin has a notable history in the biotechnology field. One of its pioneering achievements includes the establishment of fully human antibody production technology in 1997. In 2023, Kyowa Kirin expanded its capabilities by acquiring Orchard Therapeutics, a company specializing in hematopoietic stem cell gene therapy. The company continues to innovate and focus on unmet medical needs.
Sustainability and Corporate Responsibility
Kyowa Kirin is committed to sustainability and aims to contribute to the Sustainable Development Goals (SDGs). The company's research and development efforts are supported by open innovation and collaborations with various partners. Kyowa Kirin has received the highest 'Gold' recognition in the Pride Index for its initiatives supporting LGBTQ+ in the workplace and actively participated in the Tokyo Rainbow Pride 2023.
Initiatives and Collaborations
Kyowa Kirin actively engages in various initiatives to support patient care and community well-being. It celebrates Rare Disease Day annually to raise awareness for those affected by rare diseases. The company also launched the CTCL Global Care Collaborative to improve the care of Cutaneous T-Cell Lymphoma (CTCL) patients. These initiatives reflect Kyowa Kirin's commitment to patient care and social responsibility.